Bicocca Open Archive

Logo unimib boa
CORTESI, PAOLO ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.564
EU - Europa 5.751
AS - Asia 2.502
SA - Sud America 58
AF - Africa 28
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 12
Totale 18.937
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.374
IT - Italia 1.506
DE - Germania 869
SG - Singapore 849
CN - Cina 796
IE - Irlanda 665
SE - Svezia 643
RU - Federazione Russa 607
UA - Ucraina 356
HK - Hong Kong 349
GB - Regno Unito 288
FR - Francia 209
CA - Canada 175
FI - Finlandia 154
ID - Indonesia 148
DK - Danimarca 145
AT - Austria 91
IN - India 89
TR - Turchia 80
VN - Vietnam 74
NL - Olanda 51
BR - Brasile 45
BE - Belgio 43
CH - Svizzera 28
IR - Iran 25
ES - Italia 20
CZ - Repubblica Ceca 19
KR - Corea 19
AU - Australia 17
PH - Filippine 12
EU - Europa 11
PK - Pakistan 11
MX - Messico 10
RO - Romania 10
BG - Bulgaria 9
JP - Giappone 9
NO - Norvegia 8
PT - Portogallo 6
TW - Taiwan 6
ET - Etiopia 5
GR - Grecia 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
PL - Polonia 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
BD - Bangladesh 4
CL - Cile 4
GH - Ghana 4
MY - Malesia 4
AR - Argentina 3
DZ - Algeria 3
IQ - Iraq 3
LK - Sri Lanka 3
LT - Lituania 3
SC - Seychelles 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AL - Albania 2
BZ - Belize 2
CO - Colombia 2
EC - Ecuador 2
EG - Egitto 2
KE - Kenya 2
MD - Moldavia 2
MK - Macedonia 2
OM - Oman 2
PE - Perù 2
A1 - Anonimo 1
AZ - Azerbaigian 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MA - Marocco 1
ME - Montenegro 1
NI - Nicaragua 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
VG - Isole Vergini Britanniche 1
Totale 18.937
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.847
Fairfield 858
Woodbridge 832
Chandler 727
Singapore 717
Houston 662
Dublin 640
Frankfurt am Main 582
Wilmington 559
Ashburn 550
Milan 432
Santa Clara 385
Jacksonville 380
Seattle 360
Dearborn 345
Hong Kong 339
New York 331
Cambridge 280
Princeton 278
Nanjing 144
Jakarta 138
Altamura 128
Lawrence 124
Vienna 87
Shanghai 85
Helsinki 63
San Diego 62
Lachine 60
Beijing 58
Andover 51
London 51
Rome 50
Nanchang 47
Guangzhou 44
Dong Ket 43
Toronto 41
Shenyang 40
Boardman 37
Tianjin 36
Ottawa 34
Brussels 33
Fremont 33
Hebei 28
Jiaxing 28
Jinan 27
Lissone 27
Falls Church 25
Munich 25
Zhengzhou 25
Lappeenranta 24
Los Angeles 24
Redmond 24
Bologna 23
Changsha 23
Hangzhou 22
Verona 22
Ningbo 21
Paris 20
Pune 20
Washington 20
Chicago 17
Kocaeli 17
San Jose 17
Kunming 16
Mountain View 16
Norwalk 16
Parma 15
Boston 14
Legnano 13
Taizhou 13
Florence 12
Hefei 12
Monza 11
Perugia 11
Bonndorf 10
Carate Brianza 10
Edmonton 10
Naples 10
Nürnberg 10
Palermo 10
San Mateo 10
Dallas 9
Huizen 9
Montréal 9
Padova 9
Bergamo 8
Brno 8
Madrid 8
Nuremberg 8
Pavia 8
Phoenix 8
Prague 8
São Paulo 8
Tappahannock 8
Turin 8
Brescia 7
Buffalo 7
Central 7
San Francisco 7
Slough 7
Totale 13.442
Salva come PNG Salva come JPEG
Nome #
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 334
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 313
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 296
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 293
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 276
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 237
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 224
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 217
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 196
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 196
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 194
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 192
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 189
Health Related Quality of Life in the Major Liver Conditions 186
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 185
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 182
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 182
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 181
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 179
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 179
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 179
The impact of liver disease on the health-related quality of life 178
Health related quality of life in chronic liver diseases 177
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 176
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 174
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 174
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 173
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 171
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 171
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 170
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 170
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 170
Sustainability of the Italian National Health Service 169
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 168
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 168
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 167
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 167
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 165
Costs and effectiveness of influenza vaccination: A systematic review 165
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 163
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 162
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 162
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 160
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 158
The socioeconomic burden of patients affected by hemophilia with inhibitors 157
Economic Burden Of Stroke: Analysis From An Administrative Database 156
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 154
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases 153
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 152
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 152
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 149
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 146
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 145
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 145
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 144
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 142
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 141
Epidemiology and Direct Health Care Costs of Diabetic Retinopathy: Results From a Population-Based Study 141
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 141
Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A 139
Use of health care administrative databases to estimate the burden of breast cancer. 135
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 135
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 133
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 133
Incidence of inhibitors to recombinant factor VIII products – A meta-analysis of 1,852 previously untreated patients 131
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 131
Italian population-based values of EQ-5D health states 130
Preferenze della popolazione italiana per gli stati di salute dell'EQ-5D 129
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 129
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 127
Use of health care administrative databases to estimate incidence of foot complications in diabetes patients 127
Epidemiologic And Economic Burden Attributable To Atrial Fibrillation From Administrative Data 127
Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments 126
Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study 126
Utilization of antispasticity drugs in multiple sclerosis: analysis from an Italian administrative database 124
Health economic models in hemophilia A and utility assumptions from a clinician's perspective 123
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products 123
Use of healthcare administrative databases to estimate the burden of diabaetes mellitus: a population-based study 123
Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery: Analysis from an Italian Administrative Database 122
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 122
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 120
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 119
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 118
Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: Results from Italy 113
Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases 113
Utilization of disease modifying agents in multiple sclerosis: analysis from an Italian administrative database. 112
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 112
Patients’ and physicians’ needs, experiences and preferences in the treatment of rght ventricular outflow tract dysfunction. 111
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis 111
Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis 110
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 110
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation 109
Difference in health related quality of life of chronic liver diseases and general population 108
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry 108
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 107
Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data 106
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 106
Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis 106
Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study 104
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy 104
Totale 15.608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.857
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.857
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.872 0 0 0 0 0 362 422 296 330 212 206 44
2020/20212.589 178 117 297 239 258 182 230 239 202 231 148 268
2021/20221.868 137 182 253 178 130 146 64 121 109 129 106 313
2022/20233.149 327 896 275 271 212 452 57 195 222 49 100 93
2023/20242.714 98 119 93 149 295 645 397 119 233 114 146 306
2024/20252.800 352 716 355 366 610 401 0 0 0 0 0 0
Totale 20.051